DAPSONE N-ACETYLATION, METOPROLOL ALPHA-HYDROXYLATION, AND S-MEPHENYTOIN 4-HYDROXYLATION POLYMORPHISMS IN AN INDONESIAN POPULATION - A COCKTAIL AND EXTENDED PHENOTYPING ASSESSMENT TRIAL

被引:33
作者
SETIABUDY, R
KUSAKA, M
CHIBA, K
DARMANSJAH, I
ISHIZAKI, T
机构
[1] NATL MED CTR,CLIN RES INST,DIV CLIN PHARMACOL,SHINJUKU KU,TOKYO 162,JAPAN
[2] UNIV INDONESIA,SCH MED,DEPT PHARMACOL,JAKARTA,INDONESIA
关键词
D O I
10.1038/clpt.1994.117
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We examined dapsone N-acetylation and metoprolol alpha-hydroxylation and S-mephenytoin 4-hydroxylation phenotypings using the respective test probes (dapsone and racemic metoprolol and mephenytoin) administered separately and in a cocktail manner to an Indonesian subject group (n = 30). After ascertaining that the separate and cocktail phenotyping tests of the probe drugs correlated with each other (all r(s) values > 0.84; p < 0.001), the cocktail phenotyping assessment was extended to the other 74 Indonesians. In a total of 104 Indonesians phenotyped with the cocktail test, a visual antimode was apparent only in the dapsone N-acetylation and S-mephenytoin 4-hydroxylation polymorphisms: the frequencies of slow acetylators and poor hydroxylators were 43.3% (95% confidence interval, 33.7% to 52.8%) and 15.4% (95% confidence interval, 8.5% to 22.3%), respectively. The distribution histogram and probit plots of the metabolic ratio of metoprolol gave no clear evidence for bimodality, and therefore no poor alpha-hydroxylator of metoprolol was considered to exist in the present sample size. The findings indicate that the Indonesian subjects have a greater incidence of slow acetylator phenotype compared with Japanese and Chinese, as well as a frequency of poor metabolizer phenotype of S-mephenytoin similar to that of Korean and Chinese subjects. They resemble an African population (Nigerians) in metoprolol alpha-hydroxylation polymorphism, with no apparent antimode derived from white populations.
引用
收藏
页码:142 / 153
页数:12
相关论文
共 56 条
  • [1] HYDROXYLATION POLYMORPHISMS OF DEBRISOQUINE AND MEPHENYTOIN IN EUROPEAN POPULATIONS
    ALVAN, G
    BECHTEL, P
    ISELIUS, L
    GUNDERTREMY, U
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 39 (06) : 533 - 537
  • [2] PRONOUNCED DIFFERENCES BETWEEN NATIVE CHINESE AND SWEDISH POPULATIONS IN THE POLYMORPHIC HYDROXYLATIONS OF DEBRISOQUIN AND S-MEPHENYTOIN
    BERTILSSON, L
    LOU, YQ
    DU, YL
    LIU, Y
    KUANG, TY
    LIAO, XM
    WANG, KY
    REVIRIEGO, J
    ISELIUS, L
    SJOQVIST, F
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 51 (04) : 388 - 397
  • [3] ACTIVITY OF OXIDATIVE ROUTES OF METABOLISM OF DEBRISOQUIN, MEPHENYTOIN, AND DAPSONE IS UNRELATED TO THE PATHOGENESIS OF VINYL-CHLORIDE INDUCED DISEASE
    BLACK, C
    CSUKA, ME
    LUPOLI, S
    WILKINSON, GR
    BRANCH, RA
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (06) : 659 - 667
  • [4] ENANTIOSELECTIVE AMITRIPTYLINE METABOLISM IN PATIENTS PHENOTYPED FOR 2 CYTOCHROME-P450 ISOZYMES
    BREYERPFAFF, U
    PFANDL, B
    NILL, K
    NUSSER, E
    MONNEY, C
    JONZIERPEREY, M
    BAETTIG, D
    BAUMANN, P
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (04) : 350 - 358
  • [5] PROGUANIL METABOLISM IS DETERMINED BY THE MEPHENYTOIN OXIDATION POLYMORPHISM IN VIETNAMESE LIVING IN DENMARK
    BROSEN, K
    SKJELBO, E
    FLACHS, H
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (02) : 105 - 108
  • [6] RECENT DEVELOPMENTS IN HEPATIC DRUG OXIDATION - IMPLICATIONS FOR CLINICAL PHARMACOKINETICS
    BROSEN, K
    [J]. CLINICAL PHARMACOKINETICS, 1990, 18 (03) : 220 - 239
  • [7] GENETICALLY-DETERMINED VARIABILITY IN ACETYLATION AND OXIDATION - THERAPEUTIC IMPLICATIONS
    CLARK, DWJ
    [J]. DRUGS, 1985, 29 (04) : 342 - 375
  • [8] DRAYER DE, 1977, CLIN PHARMACOL THER, V22, P251
  • [9] MEPHENYTOIN AND SPARTEINE OXIDATION - GENETIC POLYMORPHISMS IN DENMARK
    DROHSE, A
    BATHUM, L
    BROSEN, K
    GRAM, LF
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 27 (05) : 620 - 625
  • [10] THE GENETIC-POLYMORPHISM OF DEBRISOQUINE SPARTEINE METABOLISM - CLINICAL ASPECTS
    EICHELBAUM, M
    GROSS, AS
    [J]. PHARMACOLOGY & THERAPEUTICS, 1990, 46 (03) : 377 - 394